bm-navigation: bm-t1-home-navigation-1

IMAGINE A WORLD IN WHICH CANCER DOESN’T WIN

bm-basic: home-our-science

OUR
MISSION

We are dedicated to developing therapeutic molecules that overcome foundational barriers that prevent patients from living longer, cancer-free lives.

About
bm-basic: home-our-programs

OUR
PROGRAMS

We recognize cancer as a chronic disease and are focused on developing therapies that address the most common cause of cancer mortality: relapse and metastasis. We believe treatments focused on modulating the foundational barriers that allow treatment-resistant cancer cells to reawaken as relapse and metastasis will meaningfully impact patient outcomes.

Programs
bm-basic: home-our-team

OUR
TEAM

We believe that overcoming foundational barriers requires collaboration of vision, scientific rigor, novel approaches and bold thought-leaders who are devoted to a shared mission.

TEAM
bm-basic: home-publications-news

HIBERCELL
NEWS

Explore our company updates and news to learn more about how we are overcoming barriers in cancer.

- Press Release

HiberCell Receives Fast Track Designation from FDA for First-in-Human Studies of PERK Inhibitor (PERKi) HC-5404-FU

Read More
- Press Release

HiberCell Expands Translational Oncology Toolbox by Acquiring Genuity Science, Inc.

Read More
- Press Release

HiberCell Appoints Mark J. Mulvihill, Ph.D., Chief Scientific Officer

Read More
VIEW ALL
bm-basic: home-work-with-us

CAREERS

Every day at HiberCell moves us closer to a world in which cancer doesn’t win.  If you share this passion, there may be a role for you on our team.

READ MORE
READ MORE
READ MORE
LEARN MORE

.